7:09 AM ET
8-K
M&A Deal
Ligand Pharmaceuticals Signs $23M M&A Deal with Sydnexis, Inc.
Ligand Pharmaceuticals acquired royalty and milestone payment rights for Ryjunea from Sydnexis for $23 million upfront. Ryjunea is a treatment for pediatric myopia licensed to Santen Pharmaceutical in the EMEA region, where it is already approved. Ligand will receive tiered royalties ranging from low-double-digits to high-teens on net sales in those territories.
- Value
- $23M
- Counterparty
- Sydnexis, Inc.